Mereo Biopharma Group Plc (MREO) is a UK-based biopharmaceutical company focused on the development of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases. The company's pipeline includes several clinical-stage product candidates, targeting various indications such as osteogenesis imperfecta, alpha-1 antitrypsin deficiency, hypogonadotropic hypogonadism, and lymphatic malformations.
Mereo's lead product candidate is setrusumab (formerly known as BPS-804), a fully human monoclonal antibody that is being developed for the treatment of osteogenesis imperfecta (OI), a rare genetic disorder that affects bone strength and causes frequent fractures. Setrusumab has been granted orphan drug designation by the US FDA and European Medicines Agency (EMA) for the treatment of OI.
Mereo is also developing alvelestat (formerly known as AZD9668), an oral small molecule inhibitor of neutrophil elastase, which is being studied in a Phase 2b clinical trial for the treatment of alpha-1 antitrypsin deficiency (AATD), a rare genetic disorder that can cause lung and liver disease. In addition, the company is developing navicixizumab (formerly known as OMP-305B83), a humanized monoclonal antibody targeting the angiopoietin-2 (ANG2) protein, for the treatment of certain types of cancer.
Mereo has collaborations with several pharmaceutical companies, including Ultragenyx Pharmaceutical, Inc. and AstraZeneca plc, to develop and commercialize certain of its product candidates. The company is headquartered in London, UK, and has additional offices in the US and Europe.
|
